Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selegiline for Smoking Cessation
NCT00129311Phase 2Completed
- Sponsor
- Yale University
- Start
- Jul 2004
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in nicotine dependence comparing Selegiline with Placebo (2 arms). Primary endpoint: 7 Day Point Prevalence of Cigarette Abstinence at 6 months. Started Jul 2004; status: completed.
02
Drugs
selegiline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT00129311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129311.